However, a meta-analysis of clinical trials in patients with COPD receiving roflumilast has revealed that treatment with this PDE4 inhibitor is associated with a significant reduction in major cardiovascular events [79]. This evidence concerns the gene PDE4A and chronic obstructive pulmonary disease.